Provided by Tiger Trade Technology Pte. Ltd.

Neurocrine Biosciences

141.25
-2.2200-1.55%
Post-market: 141.250.00000.00%19:30 EDT
Volume:1.24M
Turnover:175.17M
Market Cap:14.41B
PE:20.70
High:143.02
Open:142.88
Low:140.34
Close:143.47
52wk High:186.12
52wk Low:122.14
Shares:102.00M
Float Shares:100.00M
Volume Ratio:0.77
T/O Rate:1.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):6.82
EPS(LYR):4.67
ROE:22.09%
ROA:11.70%
PB:3.90
PE(LYR):30.25

Loading ...

New CRENESSITY Dosing Algorithms And INGREZZA Data Might Change The Case For Investing In Neurocrine Biosciences (NBIX)

Simply Wall St.
·
May 20

Bausch Health elects Eiry Roberts to board, names her science and technology chair

Reuters
·
May 20

Neurocrine’s New Tardive Dyskinesia Trial Adds Fresh Optionality for NBIX Investors

TIPRANKS
·
May 20

VistaGen appoints Angel Angelov as chief medical officer

Reuters
·
May 19

Neurocrine director Richard F. Pops disposes 15,000 shares worth $2.36 million

Reuters
·
May 19

Neurocrine Biosciences Says Data Show Functional Improvement in Tardive Dyskinesia With Ingrezza Capsules

MT Newswires Live
·
May 19

Neurocrine announces new data from a clinician survey in Ingrezza

TIPRANKS
·
May 19

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
May 18

BRIEF-Neurocrine Biosciences Completes Acquisition Of Soleno Therapeutics

Reuters
·
May 18

Neurocrine completes Soleno acquisition in USD 2.9 billion deal

Reuters
·
May 18

Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics

THOMSON REUTERS
·
May 18

Neurocrine Biosciences (NBIX) Is Up 13.6% After Q1 Beat And New CRENESSITY Data Release - Has The Bull Case Changed?

Simply Wall St.
·
May 12

Analysts’ Top Healthcare Picks: Neurocrine (NBIX), Certara (CERT)

TIPRANKS
·
May 11

Soleno Q1 FY26 net income swings to USD 31.38 million; selling, general and administrative expense rises 72% to USD 50.37 million

Reuters
·
May 08

Neurocrine Is Maintained at Buy by Truist Securities

Dow Jones
·
May 07

Neurocrine Biosciences, Inc. : Deutsche Bank Raises Target Price to $155 From $150

THOMSON REUTERS
·
May 07

Neurocrine price target raised to $207 from $190 at Piper Sandler

TIPRANKS
·
May 07

Neurocrine price target raised to $155 from $140 at Truist

TIPRANKS
·
May 07

Neurocrine Posts Strong Q1 as Key Treatments Drive Growth, Morgan Stanley Says

MT Newswires Live
·
May 06

Analysts Offer Insights on Healthcare Companies: Xencor (XNCR), DENTSPLY SIRONA (XRAY) and Neurocrine (NBIX)

TIPRANKS
·
May 06